Caris Life Sciences, Inc. (CAI)
NASDAQ: CAI · Real-Time Price · USD
28.86
+0.54 (1.91%)
At close: Dec 5, 2025, 4:00 PM EST
28.31
-0.55 (-1.91%)
After-hours: Dec 5, 2025, 6:59 PM EST

Company Description

Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally.

It develops and commercializes solutions to transform healthcare using molecular information, and machine learning algorithms.

The company’s molecular profiling services portfolio includes MI Profile, a tissue-based molecular profiling solution; and Caris Assure, a blood-based molecular profiling solution for cancer treatment.

It also offers pharma research and development services comprising laboratory delivery, strategic data, and research services to biopharmaceutical customers.

The company was founded in 2008 and is headquartered in Irving, Texas.

Caris Life Sciences, Inc.
Caris Life Sciences logo
Country United States
Founded 2008
IPO Date Jun 18, 2025
Industry Biotechnology
Sector Healthcare
Employees 1,769
CEO David Halbert

Contact Details

Address:
750 West John Carpenter Freeway, Suite 800
Irving, Texas 75039
United States
Phone 866 771 8946
Website carislifesciences.com

Stock Details

Ticker Symbol CAI
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
IPO Price $21.00
CIK Code 0002019410
CUSIP Number 142152107
ISIN Number US1421521071
Employer ID 85-2077369
SIC Code 8071

Key Executives

Name Position
Dr. David Dean Halbert M.D. Chairman, Chief Executive Officer and Founder
Brian J. Brille J.D. Executive Vice Chairman and Executive Vice President
Dr. David Spetzler M.B.A., M.S., MBA, MS, Ph.D. President
Luke Power Senior Vice President, Chief Financial Officer and Chief Accounting Officer
Jon Mark Harmon Senior Vice President and Chief Operations Officer
Dr. Valeriy Domenyuk Senior Vice President and Chief Technology Officer
Dr. Milan Radovich Ph.D. Senior Vice President and Chief Scientific Officer
Ginger Appleberry J.D. Senior Vice President, Deputy General Counsel and Chief Compliance Officer
J. Russel Denton Senior Vice President, General Counsel and Secretary
Narendra Chokshi Senior Vice President of Corporate Development

Latest SEC Filings

Date Type Title
Nov 5, 2025 10-Q Quarterly Report
Nov 5, 2025 8-K Current Report
Oct 30, 2025 8-K Current Report
Aug 14, 2025 SCHEDULE 13G Filing
Aug 13, 2025 SCHEDULE 13G Filing
Aug 12, 2025 10-Q Quarterly Report
Aug 12, 2025 8-K Current Report
Jul 28, 2025 SCHEDULE 13G Filing
Jun 24, 2025 SCHEDULE 13G Filing
Jun 20, 2025 8-K Current Report